AP873A

AP873A - Microcapsules containing suspensions of biologically active compounds and ultraviolet protectant.

Info

Publication number: AP873A
Application number: APAP/P/1997/001130A
Authority: AP
Inventors: Scher Herbert Benson; Chen Jin Ling
Original assignee: Syngenta Ltd
Priority date: 1995-04-27
Filing date: 1996-04-18
Publication date: 2000-09-11
Also published as: CO5040219A1; TR199701259T1; US6077522A; NO312572B1; CN1185090A; UA46025C2; NO974947L; BG63522B1; EA199700343A1; US6149843A; OA10530A; EP0824313A2; HUP9900466A3; WO1996033611A3; DE69609712T2; WO1996033611A2; CA2219001A1; NZ305421A; DE69609712D1; AP9701130A0

Abstract

Microcapsules containing a biologically active material which is sensitive to ultraviolet light are prepared which contain an ultraviolet light processer selected from lithum dioxide zinc oxide and mixtures thereof suspended and thoroughly dispersed in a liquid

Description

MICRQCAPSt’LES CONTAINING SUSPENSIONS

OF BIOLOGICALLY ACTIVE COMPOUNDS

AND ULTRAVIOLET PROTECTANT

Back2rqund__and Prior Art

This invention pertains to an improvement in the invention described in PCT International Publication No. WO95/13698. and in particular in producing microcapsules containing biologically active compounds and further containing a suspended ultraviolet protectant agent.

As pointed out in WO95/13698, while various types of microencapsulation techniques have been used to prepare microcapsules of biologically active compounds for pesticidal use. no satisfactory techniques to produce a microcapsule containing a solid biologically active pesticide suspended in a liquid had previously been known. There were several reasons for this, particularly the following difficulties:

1. It is necessary to produce a stable suspension of the Biologically active solid in a water-immiscible liquid. If dispersants or surfactants are used, they must not interfere with further processes of dispersion used in making the micrccapsules.

2. The suspension of the solid must be dispersed in water to produce stable well-dispersed droplets, preferably very small droplets of an organic-phase suspension dispersed in water. This requires high shear forces which would tend to break down the droplets and/or release the solid from suspension.

3. The presence of one or more surractants can make the dispersed droplet system unstable and proauce phase inversion.

AP/P/ 9 7/01 130

APO 0 0 8 7 3

4. The suspended solid is liable to migrate to the aqueous phase, particularly when emulsifying surfactants are used.

WO95/13698 describes techniques for producing microencapsulated formulauons of a soiid biologically active compound suspended in a liquid. The product is produced by essentially a three-step process. In the first step, the solid biologically active material is produced with a required panicle size, for example by a milling process. In the second step, the solid biologically active compound is suspended in an organic liquid, preferably one which is a poor solvent for the solid and which is immiscible with water. The liquid, however, must be polar enough to dissolve the prepolymers used in the microencapsulation process. Alternatively, the solid may be first suspended in a liquid and then milled. In the third step, a physical dispersion of this water immiscible phase in an aquepus phase is prepared.

Some biologically active materials are adversely affected by ultraviolet or actinic light: even when they are microencapsulated, the active material in. the capsule may still became degraded in the presence of light. A number of techniques have been proposed to provide ultraviolet light protection to microencapsulated materials. For example. Ignoffo et al.. J. Economic Entomology, 64. 850 (1971) discloses use of cellulose, carbon, aluminum powder and aluminum oxide in protecting encapsulated virus samples from ultraviolet radiation. The authors do not describe ihe process by which the microcapsules were prepared. U.S. Patent 3.541.203 describes the use of carbon black and other ultraviolet absorbers such as metal flakes, metal oxide panicles, metal sulfides and other commonly used pigments to provide ultraviolet protection to a virus contained within a polymeric matrix. U.S. Patents 4,344,896 and 4,948.536 disclose the use of a number of organic dyes and other sunscrceaing agents such as benzophenone. PABA and benzil for mixtures thereof) for protection of encapsulated viruses. U.S. Patent 4.32S.203 discloses production of a microencapsulated pathogenic viral, bacterial or fungal material in a coacervate microbead comprised of a nucleic acid and a proteinaceous material, in which the microbead structure itself is a UV protectant. Finally, PCT application WO92/19102 discloses another type of microcapsuie in which Ihe encapsulating agent itself, this time lignin, also serves as the sunscreen.

AP/P/ 9 7 / 0 1130

ΑΡΟ 0 0 8 7 3

Π *0*

Summary of the invention

This invention comprises microcapsuies and a process for their preparation, and in particular comprises (1] a microcapsule containing a liquid comprising an ultraviolet light sensitive, biologically active compound and an effective amount of a particulate ultraviolet light protectant selected from titanium dioxide, zinc oxide and mixtures thereof suspended and thoroughly dispersed in the liquid; and (2] a process for preparing microcapsules containing an ultraviolet light sensitive biologically active compound which comprises a liquid and an effective amount of a paniculate ultraviolet light protectant selected from titanium dioxide, tine oxide and mixtures thereof suspended and thoroughly dispersed in the liquid, comprising the steps of; (a) preparing a suspension of the ultraviolet light protectant having average panicle size of about Q.QI-2 microns in an organic liquid which is immiscible with water and which contains an ultraviolet light sensitive biologically active material, in which the protectant is thoroughly dispersed in ihe liquid: (b) introducing the suspension of step (a) into water containing a protective colloid and optionally a surfactant capable of maintaining the organic liquid as droplets in the water without extracting solids from the organic liquid into the water, the organic liquid containing m solution one or more prepoivmers which can react to form a polymer at the interface of the organic liquid and water; (c) mixing the suspension of organic liquid in the aqueous phase under high shear to form an οιί-in-waier emulsion: and (d) adjusting, if necessary, the temperature and/or pH of the oil-in-waier emulsion such that a polymerization reaction takes place at the organic liquid/water interface to form the microcapsules.

AP/P/ 9 7/01130

Dttailtd .Dasicriptioti of thslimntion

In general, the invention uses the process described in WQ95/13698 to produce microcansuies. This technique wiil be described herein. In the parent application, the technique was utilized for producing microcapsules containing a suspension of a biologically active solid in a liquid. In the preseni invention, the technique is utilized forpreparing a suspension of a solid ultraviolet light protectant material in a liquid which

AP ο Ο Ο 8 7 3 comprises biologically active maxenal. By comprises. it is meant that the biologically active material may also be in the form of a solid suspended in the liquid- or may be dissolved in the liquid, or may itself constitute the liquid in which the ultraviolet light protectant is suspended. In another embodiment, the microcapsule may contain a suspension of a solid biologically active compound in a liquid which comprises a second biologically active compound (for example, the second biologically active compound is the liquid or is dissolved in the liquid!, and which also contains a thoroughly dispersed particulate ultraviolet light protectant

The biologically active material which is to be protected in this invention may be any of those known to be subject to degradation or decomposition by ultraviolet light. Notable among such compound^ are the pyrethroids and pyretnrins. Many of the pyrcthxoids are known to be susceptible to degradation by ultraviolet light including pennethrin. cypermethrm. deltamcthrin. fenvalerate, cyfluthrin. resmethrin. allethrin, etofenprox. and lambda-cyhalothrin. Other biologically active materials which are known to be susceptible to degradation or decomposition by ultraviolet light include the herbicides trifiuralin, ioxynil and napropamide. the insecticides pirimiphos-methyl and chlorpyrifos and the fungicide azoxystrobin. Microcapsules of this invention may contain two or more ultraviolet light sensitive biologically active materials.

The liquid utilized in this invention may be a liquid biologically active material which itself is susceptible to degradation by ultraviolet light, or a biologically active material which is not normally so susceptible (but in which there is suspended a second biologically active material which is light-sensttivei, or an organic solvent which is immiscible in water and in which the ultraviolet light sensitive material is suspended or dissolved. The liquid, in any case, should be sufficiently polar to dissolve the prepolymer or prepolymers used to form the microcapsule wall.

For solvents, suitable examples are (depending on the types of microcapsule) aromatic hydrocarbons such as xylenes or naphthalenes, aliphatic solvents such as aliphatic or cycloaliphatic hydrocarbons, e.g.. hexane, heptane and cyclohexane, alkyl esters including

AP/P/ 9 7/01 130

AP000873

-5alkyl aceiaies and alkyl phthalates, ketones such as cyclohexanone or acetophenone, chlorinated, hydrocarbons, and vegetable oils. The solvent may be a mixture of rwo or more of the above solvents.

The preferred materials for the microcapsuic wall may be any of those commonly used. Two examples are a polyurea, formed as described in U.S. Parent d.?S5.770 or a urea-formaldehyde poiymer as described in U.S. Patent 4,956.129.

The ultraviolet light protectant used in this invention is titanium dioxide, zinc oxide, or a mixture of titanium dioxide and zinc oxide. In general, the ultraviolet light protectant is used in an amount of from about 0.1 to about 50 weight %. preferably from about 1 to about 10 weight %. with respect to the organic phase. Mixtures of titanium dioxide and zinc oxide will contain these two substances in a weight ratio of from about T.10 to about 10:1.

The process comprises the following steps:

Step 1. Obtaining the ultraviolet light protectant with a preferred particle size. The protectant may be commercially available in the desired panicle size. If not. it is suitably by a milling process. The preferred average panicle size of this protectant is about 0-01-2 microns, preferably about 0.02-0.5 microns. If the microcapsules are to contain a solid biologically active material suspended in the liquid- that material should have an average panicle si2c of from about 0.01 to about 50. preferably from about 1 to about 10. microns.

Step 2. Suspending the ultraviolet light protectant in an organic liquid. The liquid must be immiscible with water, but polar enough to dissolve the prepoiymeis used in the microencapsulation process. The ultraviolet light protectant must also be thoroughly dispersed in the liquid: i.e.. dispersed into individual particles that are not agglomerated.

The dispersion is preferably carried out by means of a dispersant which is capable of keeping the protectant solid in the liquid but which does not allow the solid to be

AP/P/ 9 7/01130

AP000873

-6extmcted into the water when the suspension is dispersed into water. In addition, when the suspension is added to water, the dispersant must not allow phase inversion to occur, i.e„ the water must not be allowed to be taken into the organic liquid to form a water-tn-oil emulsion.

The exact choice of dispersants will depend on the nature of the ultraviolet light protectant and the type of organic liquid. Preferred dispersants are certain nonionic surfactants which act by stenc hindrance and are active only at the protectant solid/organic liquid interface and do not act as emulsifying agents. Such dispersants are suitably made up of (a) a polymeric chain having a strong affinity for the liquid and fb) a group which will absorb scrongiy to the solid. Examples of such dispersants arc those of the Hypenner and Atfox lines, available from the ICI group of companies, including Hypermer P51, Hypenner PS2. Hypermer PS3. Atlox LPl. Atlox LPl. Atlox LP4. Atlox LP5. Atlox LP6. and Atlox 4912: and Agnmer polymers such as Agnmer aL-216 and AL-220. available from GAP.

In general, the ranee of dispersant concentration used is from about 0.01 to about 10 percent by weight based on the organic phase, but higher concentrations of dispersant may also be used.

If the microcapsules also contain a suspended solid biologically active material, the same considerations appiy with respect to suspending and dispersing it as are mentioned above for the ultraviolet light protectant.

Alternatively, the procedures of these steps I and 2 above may be varied by first suspending and dispersing the ultraviolet light protectant in the organic liquid, with the protectant having a particle size larger than that mentioned above, and then conducting a milling process (media milling) to reduce the particle size of the protectant to that mentioned above.

* 0 £ I 1 o / L 6 /d/dV in anv event, no matter exactly how tt is accomplished, the ultraviolet light protectant must be thoroughly dispersed in :he organic phase.

OCT '37 22=25 .009

AP000873

Step 3: A physical dispersion of a water-immiscible phase in an aqueous phase is prepared. To obtain the appropriate dispersion, the organic phase is j₀ m.e aqueous phase, with stimna. A suitable dispersing means is employed to disperse the organic phase in the liquid phase. The means may be any high shear device, so as to obtain a desired average droplet (and. corresponding microcapsule particle) size within the range or from about 1 to about 200 microns. Preferably the average droplet size is from about I to about 30 microns, most preferably from about 2 to about 20 microns. Once the proper droplet size is obtained, the dispersion means is discontinued. Only mild agimion is required for the remainder of the process. The water-immiscible (organic liquid) phase comprises the solid ultraviolet light protectant and optionally also a solid biologically active material suspended in the liquid to be encapsulated, prepared as described above in Steps 1 and 2. The aqueous ptiase is comprised of water ano a material termed a protective colloid. Preferably it further contains a surfactant

In general, the suriactanr or surfactants in the aqueous phase may be anionic or non-ionic surfactants with an HLS range of from about 12 to about 16 that is high enough to form a stable οίΐ-in-water emulsion. If more than one surfactant is used, the individual surfactants may have values lower than 12 or higher than 16 as long as the overall HLB value of the surfactants when combinea will be in the ranee of 12-16. Suitable surfactants include polyethylene glycol ethers of linear alconois. etnoxvlated nonylphenols, naphthalene sulfonates. salts of long chain alkylbenzcne sulfonates, block copolymers of propylene oxide and ethylene oxide and anionic/nomonic blends. Preferably the hydrophobic portion of the surfactant has chemical characteristics similar io the organic liquid. Thus, when the organic liquid is an aromatic solvent, the surfactant would suitably be an ethaxylaicd nonyiphenoh

Especially preferred surfactants are Tergitol NP7. Terzitol XD. Tergitol NP40 and Tergitol I5-S-20. available from Union Carbide and Witconate 90, available from Witco.

In general, the range of surfactant concentration in the process is from about 0.Q1 to about 10.0 percent by weight, based on the aqueous phase, but higher concentrations of surfactant may also be used.

AP/P/ 9 7 / 0 1130

APO 0 0 8 7 3

-sThe protective colloid present in the aqueous (continuous) phase must absorb strongly onto the surface of the oil drooiets. Suitable colloid-forming materials include one or more of polvacrylaies. rnetnvi cellulose- polyvinyl alcohol, poiyacr/iaxnide. poiyimethvl vinyl ether/maleic anhydride), grar'i copolymers of polyvinyi alcohol and methylvinyl ether/maieic acid (hydrolyzed methyivinyi ether/maleic anhydride; see U.S. Patent 4,448.929. which is hereby incorporated by reference herein), and alkali metal or alkaline earth metal lignosulfonates, Preferably, however, the protective colloid is selected from alkali metal and alkaline earth metal lignosuifonates, most preferably sodium lignosulfonates.

There must be sufficient colloid present to afford complete coverage of the surfaces or all the droplets ot the organic liquid. The amount of protective colloid employed will depend On various factors, sucn as moiecuiar weighu compatibility, etc. The protective colloid can be added to the aqueous phase prior to the addition of the organic phase, or can be added to the overall system arter the addition of the organic phase or the dispersion of it. The protective colloid is generally present in the aqueous phase in an amount of from about 0.1 to about 10,0 percent by weight.

Any surfactant used in the aqueous phase must not displace the protective colloid from the surface of the droplets of organic liquid.

The preferrea average panicle size of the droplets of the waier-immiscible liquid containing a biologically active solid is 1-200 microns, preferably [-30 microns and more preferably 2-20 microns. Panicle size can be adjusted according to the and use of the microcapsules by adjusting stimng speed and time, and by the choice of surfactants and the amount of surfactants employed.

In order to obtain the microcapsules. the organic liquid and/or the water must contain one or more materials which can react to form a polymer at the interface between the organic liquid and the water.

In the orocess described in U.S, Patent 4.2S5.720. ooivisocyanates are dissolved

AP/P/ 9 7 /01130

APO00873

-9in (he organic phase ii.e., at Seep 2 in (he above procedure; and polymenzarion takes place by hydrolysis of the crepoiymers at the watcr/orgaruc liquid interface to form amines which, m tum. react with unnydrotyzed monomers to form the poiyurea microcapsuie wail. A single compound or a mixture of two or more polvisocyanates may be used. Of the poiyisocyanaics. poiy methylene polypheny [isocyanate and isomeric mixtures of toluene diisocyanate are preferred. Particularly preferred arc mixtures of poiymethylene polyphcnyiisocyanare with isomeric mixtures of toluene diisccyanate.

The amount of the organic polyisocyanate used in the process will determine the wall content of the microcapsuies formed. In general, the poiyisocyanate tor microcapsuie wall formed from iti content will comprise from about 2.0 to about 75.0 percent by weight of the microcapsuie. Most preferaoiy the wail wtil comprise from aboui 4 to about 15% by weight of the microcapsuie.

The dispersion is maintained in a temperature range of from about 20°C to about 90^eC, preferably from about 40’ to about 60^eC, dunng which the condensation reaction cakes place to form ihe polyurea at the interfaces between the droplets of the organic phase and the aqueous phase.

Another suitable system for forming microcapsuies is described in L'.S. 4.956.129. in which the polymer is formed from an ethenned urea-formaldehyde prcpolymer in which 50-98% of the methyloi groups have been etherined with a C₄-C,q alcohol. The prepolvmer is added to the organic phase. Self-condensation of the prepoiymer takes place under the action of heat at low pH.

To form the microcapsuies. the temperature of the two-phase mixture is raised to a value of from about 20’C to about 90^cC. preferably from about 40’C to about 90°C, most preferably from about 4C’C to about 60°C. Depending on the system, the pH value may be adjusted to an appropriate ievsl. For the purpose of this invention a pH of 2 ts appropriate.

AP/P/ 9 7/01130

AP Ο ύ Ο 8 7 3

-10The r'ollowtng axe examples or' preparations of compositions of this invention. Ingredients used in the following examples were:

• lambda-cyhaiothnn. technical grade (88% purity >

• Soivesso 200 aromatic solvent (available from Exxon) • titanium cioxide - Examples I and 2. t⁷SP32S - 0.3 micron panicle size, from Whittaker. Clark &. Daniels Lid.; Example 3; Tiosorb UFO2. 0.02 micron size, from Tioxide Specialties Ltd.

• Hypermer JLPl. Hypermer LP5 ano Atlox 4912 dispersants (available from ICTI • Reax 100M protective colloid (sodium salt of lignosulfcmc acid. 40% wl solution in water, available trom W'estvaco Chemicals • Keizan ixanthan gum. available from Monsanto • Proxei GXL i biocide, available from 1CI1 <9

The amounts of the ingredients are given in the examples.

General Procedure

A solution of lambda-cyhalotnnn m Soivesso 200 solvent was prepared. The dispersants were added, followed by (he titanium dioxide, and the resulting suspension agitated with a high shear stirrer. After the titanium dioxide was weli dispersed, polymethylene polyphenyiisocyancte and toluene diisocyanate were added to complete the organic phase.

AP/P/ 9 7/01130

This phase was introduced tc the aqueous phase with agitation with a high shear stirrer to form an oil-in-water emulsion. The average droplet size was 3.0 ± 1 microns (Examples 1 and 2) and about 12 microns (Example 2). The temperature was then raised to 50^oC over a 30-minute penoa wniie maintaining miid agitation, and then maintained at 50^eC for 3 hours. The resulting suspension of microcapsuies was allowed to cool to room temperature. In Examples I ana 2 the additional ingredients were added (to improve the properties or (he aaueous suspension of micrccacsulesj and the pH was adjusted to 5.0 with sulfuric acid.

APO 0 0 8 7 3

1Example 1 Compesizian

Component	Weight, q	weight, a.
ORGANIC PHASE
Lambda-cy hai o thri n	112.2	2S.3
Solvssso 200	58.4	14.6
Titanium dioxide	9.7	2.4
Hypermer LP5 5»	6.1	* 1.5
Hypermer LP1	2.1	0.5
Isocyanates	15.3	3.8
AQUEOUS PHASS
Reax JOOM	10.5	2.6
Witconate 90	1.0	0.3
Tergttol XE>	3.1	0.8
Water	176.5	44.2
additional ingredients
Ammonia (30%wt aqueous solution»	2.0	0.5
Kelzan	0.5	0.1
Proxel GXL	0.4	0-1
Concentrated Sulfuric Acid	1.2	0.3

AP/P/ 9 7/01 130

TOTAL

400.0 100.0 ΑΡΟ00873

-12Example 1

Composition

Gamparani

ORGANIC.. PHASE.

Lambda-cyhalotnnr. Solvesso 200

Titanium dioxios

Atlox 4912 Isocyanates

Weight. i[	weight.
113.2	2S.3
58.4	14,6
9.7	2-4
S.2	2.0
15.3	3.8

A.Q.VEQVS PRASE

Reax 100M	10.5	2.6
Wjtconate 90	1.0	0.3
Tergitol XD	3.3	0.8
Water	176.5	44.2

AP/P/ 97/01130

ADDITIONAL INGREDIENTS

Ammonia <309&wt aqueous solution

Kelzan

Proxel GXL

Concentrated Sulfuric Acid

2.0	0.5
0.5	0.1
0.4	0.1
1.2	0.3

TOTAL

400.0 100.0

OCT '37 22:23 t* r

APO 0 0 8 7 3 •13Example 3

Composition

Component QRGAMK PHASE	-Weight, 2 Weicht.
Napropamide (technical gradei	52.0	13.0
Solvesso 200	94.1	23.5
Titanium dioxide	51.5 ,	7.9
Hypermer LP6	8.4	2.0
Isocyanates	14.7	3.7
AQUEOUS PHASE
Reax 100M	14.7	3/7
Tergitol 15-S-7 (20%wt aqueous solutioni	12.6	3.2
Gelvatol 40/10 (20%wt aqueous solution)	9.5	2.4
Water	162.5	40.6

AP/P/ 97/0 1 130

TOTAL

400.Q IOO.Q

APO 0 0 8 7 3

-14DETERMINATION ΟΓ PROTECTIVE EFFECT

Glass Slide Evaluation

A sample of microcapsuies containing titanium dioxide prepared as in Example 1 (according to the invention: indicated in Table 1 as Example 1 b) was spread on a glass slide and exposed to a xenon tamp (Simulating sunlight) for up to three days. Comparative tests were conducted with identical amounts of microcapsules similarly prepared, but differing from that of the invention as indicated beiow m containing a different ultraviolet light protectant (Example la), similarly containing titanium dioxide but lacking a dispersant (Example lc). prepared utilizing titanium dioxide in (he aqueous phase only (Example I d) or lacking an » ultraviolet light protectant (Example lei. The microcapsuies were analyzed to determine the amount of lambda-cyhalothnn, present in the formulations at the initiation of exposure to ultraviolet light and (he amount present after one and three days' exposure.

As can be seen from the results in the following Table I. microcapsuies produced according to this invention (Example lb) provided the best protection against degradation of lambda-cyhaiothrin by ultraviolet light. After one day’s exposure, most of the lambda-cyhalothnn was still present, whereas with the comparative microcapsuies the amount of lambda-cyhaiothrin remaining ranged from approximately one-fourth to nearly one-sixth of the original amount. Even after three days' exposure, microcapsuies of this invention still contained nearly one-naif of the lambda-cyhaiothrin originally present.

AP/P/97/0 1 130

EXAMPLE

APOΟ Ο 873

-15TABLE I

LiV PROTECT ANT % lambda-cyhalqthrin REMAINING AFTER IRRADIATION

WT, S..J3H

EQRMIL

ΣΪ2Ε- um Ω-DAYS. 1 DAY 3 DAYS

la	Waxoline black + Hypermer dispersants	2.5	100	17.9
lb	Titanium dioxide + Hypermer dispersants	2.5	100	32.1
1c	Titanium dioxide without dispersants	2.5	100	20.8
Id	Titanium dioxide outside capsuie -- in aqueous phase oniy	2.5	100	17.9
le	None	.. .	100	24.2

AP/P/ 9 7/01130

Ealiar Persistence on Cotton

A sample of the material designated above is Example lb was tested in comparison with microcapsules similarly prepared containing the same amount of lambdacyhalothrin but having no titanium dioxide and no dispersants.

All samples of microcapsules were diluted with water and sprayed on cotton plants at an application rate of 50 g iambda-cyhalothrin/hsctare.

Leaf samples from me cotton were taken and processed as follows, with two replicates for each treatment, each tune, being taken.

APOΟ 0 8 7 3

-16Each replicate involved excising three well exposed leaves, placing them in a glass jar. adding 500 mt acetone, closing the jars and shaking well for 30-45 seconds. The leaves were then carefully out quickly removed, flattened while still drying, sandwiched between sheets of transparent plastic, and photocopied. The leaves were disposed of and their size was measured from the photocopies using an image analyzer.

Then. 2 mi of the mobile pnase was added to the samples, the contents of the jar were shaken vigorously and then filtered and analyzed by reverse phase high pressure liquid chromatography.

Samples were taken at 24.48. 72. 96. and 190 hours after application. Figure I shows, in graphical form, a comparison oHhe retention of lambda-cyhalothrin in the iwo formulations tested - one according to the invention, the other identical but without the titanium dioxide and dispersants, and demonstrates the protection of lambda-cyhalothrin in the product of this invention as compared to capsules lacking the protectant.

Claims

WHAT IS CLAIMED IS:

AP ο ο o 8 7 3

-17Having now particularly described and ascertained my/oursaid invent Un in what manner the same is to be j’erh.rmcd I/we declare that what I/we claim is —

1. A microcapsuie containing an organic liquid comprising an ultraviolet light sensitive, biologically active matenai. ana an effective amount of a particulate ultraviolet light protectant selected from titanium dioxide. 2inc oxide and mixtures thereof suspended and thoroughly dispersed in the liquid.
2. A microcapsuie according to Claim 1 in which the biologically acnve material is suspended in the liquid.
3. A microcapsuie according to Claim 1 in which the biologically active material is dissolved in the liquid or comprises the liquid
4. A microcapsuie according to Claim 1 m which the particle size of the ultraviolet light protectant is from about 0.01 :o about 2 microns.
5. A process according to Claim 1 in which the particle size of the ultraviolet light protectant is from about 0.02 to about 0.5 microns.
6. A microcapsuie according to Claim 1 in which the ultraviolet light protectant is titanium dioxide.
7. a mixture according to Claim i in which the ultraviolet light protectant is a mixture of titanium dioxide and zinc oxide.
8. A microcapsuie according to Claim 1 in which the biologically active material comprises a pyrethroio.
9. A microcapsuie according to Claim 1 in which the biologically active material comprises lambda-cyhalothnn.

AP/P/ 9 7/01 130

APO00873 •1810. A microcaasule according to Claim 1 wherein the capsule walls are formed of polyurex
11. A microcapsule according to Claim 1 wherein the capsule wails are formed of a urea-formaldehyde polymer.
12. A process for preparing microcapsules containing a liquid comprising an ultraviolet light sensitive, biologically active material and an effective amount of a paniculate ultraviolet light protectant selected from titanium dioxide, zinc oxide and mixtures thereof suspended and thoroughly dispersed in the liquid, comprising the steps of (a) preparing a suspension of the protectant having an average panicle size of from about 0.01 to about 2 microns in an organic liquid which is immiscible with water and which contains an ultraviolet light sensitive, biologically active material, in which the protectant is thoroughly dispersed in the liquid: (b) introducing the suspension into water containing a protective colloid and optionally a surfactant capable of maintaining the organic liquid as droplets in the water without extracting the protectant from the organic liquid into the water, the organic liquid containing in solution one or more prepolymers which can react to form a polymer at die interface of the organic liquid and water: (cl mixing the suspension cf organic liquid in the aqueous phase under high snear to form an oil in water emulsion: and id) adjusting as necessary the temperature and/or pH of the oil in water emulsion such that a polymerization reaction takes place at the organic liquid/water interface to form the microcapsules.
13. A process according to Claim 12 in which the biologically active material is a solid which is suspended in the liquid.

1-t. A process according to Claim 13 in which the biologically active material has an average panicle size of from about 0.01 to about 50 microns.

! 5. A process according to Claim 12 in which the biologically active material is dissolved in the liquid.

AP/P/ 9 7/01130

22 OCT ’3? 22:32

Pft<32.22 1

ΑΡΟ00873

-1916. A process according to Claim 12 in which the particle size of the droplets of organic liquid, after dispersion m the water, is from about 1 to about 20 microns.
17. A process according to Claim 12 in which the prepoiymer comprises one or more organic polvisocyanates dissolved in the organic liquid wnich. when heared, forms a polyurea by hydrolysis of an isocyanate to an amine which, in turn, reacts with another isocyanate to form the polyurea.
18. A process according to Claim 17 in which the prepoiymer is a mixture or polymethylene polyphenyhsocyanate and an isomeric mixture of toluene diisneyanate.
19. A process according to Cjaim i2 in which the prepoivmer is a ureaformaldehyde prepoivmer in whicn about 50-98% of the methylol groups have been ethenfied with a C₄-C._o alcohol, and which forms a soiid polymer at the organic liquid/water interface.
20. A process according to Claim 19 in which about 70-90% of the methylol groups of the prepoiymer have been ethenfied with n-butanol.
21. A process according to Claim 12 in which the ultraviolet light protectant particles are thorougnlv dispersed in the liquid by means of a dispersant.
22. A process according to Claim 21 in which the dispersant is a nonionic surfactant.

AP/P/ 9 7/01130
23. A process according to Claim 12 in which the microcapsules have an average panicle size of about 1-200 microns.

34. A process according to Claim 12 in which the biologically active material comprises a pvrethroid.

APOΟ 08 7 3

-2025. A process according to Claim 12 of which the biologically active material comprises lambda-cyhalorhrin.
26. A microcapsule containing an organic liquid and an effective amount of a particulate ultraviolet light protectant selected from titanium dioxide, zinc oxide and mixtures thereof suspended and thoroughly dispersed in the liquid.
27. A microcapsule according to Claim 26 in which the particles are maintained thoroughly dispersed in the liquid by means of a dispersant.
28. A process for preparing microcapsules containing a liquid comprising an effective amount of a particulate ultraviolet light protectant selected from titanium dioxide, zinc oxide and mixtures thereof suspended and thoroughly dispersed in the liquid, comprising the steps of (a) preparing a suspension of the protectant having an average particle size of from about 0.01 to about 2 microns in an organic liquid which is immiscible with water, the particles being suspended and thoroughly dispersed in the organic liquid; (b) introducing the suspension into water containing a protective colloid and optionally a surfactant capable of maintaining the organic liquid as droplets in the water without extracting the protectant from the organic liquid into the water, the organic liquid containing in solution one or more prepolymers which can react to form a polymer at the interface of the organic liquid and water; (c) mixing the suspension of the organic liquid in the aqueous phase under high shear to form an oil in water emulsion; and (d) adjusting as necessary the temperature and/or pH of the oil in water emulsion such that a polymerization reaction takes place at the organic liquid/water interface to form the microcapsules.
29. A process according to Claim 28 in which the organic liquid contains a dispersant.
30. A suspension of an effective amount of a particulate ultraviolet light protectant selected from titanium dioxide, zinc oxide and mixtures thereof in an organic liquid, the particles being suspended and thoroughly dispersed in the liquid.
31. A suspension according to Claim 29 in which the particles are maintained thoroughly dispersed in the liquid by means of dispersant.